Home Companies Catalysts Deep Dives
LTSE-2578 LTSE-2578 PHASE1
Drug Profile
ModalitySmall molecule
RouteORAL
Therapy AreaR&I
Formulations[{"id":"ltse-oral-1","route":"ORAL","device":"Tablet","setting":"PATIENT_SELF","duration":null,"freq
Companies
GPCR (ORIGINATOR)100%
Mechanism: LPA1 receptor antagonist
Expert: Antagonist of the lysophosphatidic acid receptor 1 (LPA1/LPAR1), blocking pro-fibrotic signaling implicated in idiopathic pulmonary fibrosis pathogenesis.
Everyday: A drug that blocks a receptor involved in lung scarring to potentially treat pulmonary fibrosis.
Targets: ["LPA1"]
Programs (1)
IndicationStageKey StudyRegional Status
IPFPHASE1Phase 1 (complete)[]
Upcoming Catalysts (1)
LTSE-2578 - IPF - Ph2 Potential Start 2026
Notes
Phase 1 complete. LPA1 receptor antagonist for idiopathic pulmonary fibrosis. No dose-dependent adverse events or serious adverse events in Phase 1. Non-core asset outside metabolic focus.
Data from Supabase · Updated 2026-03-24